Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centrexion Therapeutics Corporation operates in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These matters are both located within 1 distinct art unit, indicating that the company's current prosecution is focused on a specific regulatory and technical niche.
The 2 pending office actions are assigned to 2 distinct examiners. HEASLEY, MEGHAN CHRISTINE is the busiest examiner, managing 1 pending office action. This arrangement shows that while the applications are in the same art unit, they are being reviewed by different individuals, which could lead to different timelines for the 2 pending office actions.
Practitioners should prepare for the specific nuances of the Biotechnology & Pharmaceuticals field while dealing with 2 distinct examiners. Since HEASLEY, MEGHAN CHRISTINE is responsible for 1 pending office action, the workload is evenly split. The concentration in 1 distinct art unit suggests that the company can apply a consistent procedural strategy, even as it addresses the unique substantive concerns of the 2 distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEASLEY, MEGHAN CHRISTINE | 1 | 75.2% | +34.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18947057 | CAPSAICIN SEQUENTIAL DOSING METHOD FOR TREATMENT OF KNEE JOINT PAIN | HEASLEY, MEGHAN CHRISTINE | — |
| 18674288 | STABLE AQUEOUS CAPSAICIN INJECTABLE FORMULATIONS AND MEDICAL USES THEREOF | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947057 | CAPSAICIN SEQUENTIAL DOSING METHOD FOR TREATMENT OF KNEE JOINT PAIN | HEASLEY, MEGHAN CHRISTINE | — | §103Other | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18674288 | STABLE AQUEOUS CAPSAICIN INJECTABLE FORMULATIONS AND MEDICAL USES THEREOF | SZNAIDMAN, MARCOS L | 1628 | DP | Non-Final OA | — | Pending | May 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial